We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+13.19%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.1B
AUM Growth
+$1.25B
Cap. Flow
-$1.53B
Cap. Flow %
-12.71%
Top 10 Hldgs %
75.84%
Holding
141
New
6
Increased
25
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$90.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$52.6M
3
DYAX
DYAX CORPORATION
DYAX
+$24.1M
4
ALKS icon
Alkermes
ALKS
+$17.5M
5
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$15.8M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$18.6M
2
XNPT
XENOPORT, INC.
XNPT
+$17M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$16.8M
4
RPRX
Repros Therapeutics Inc.
RPRX
+$14.5M
5
LRMR icon
Larimar Therapeutics
LRMR
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 73.26%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.3B
$2.11B 17.5%
19,475,316
+347
+0% +$38.7K
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$1.67B 13.87%
37,293,728
+1,263,982
+4% +$52.6M
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$1.25B 10.34%
6,542,599
– –
ABBV icon
4
AbbVie
ABBV
$472B
$851M 7.05%
14,373,538
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.46B
$730M 6.05%
20,481,442
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$481M 3.98%
13,659,264
+936
+0% +$25.1K
ANAC
7
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$474M 3.93%
4,198,520
+63,108
+2% +$6.95M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12B
$431M 3.57%
4,115,083
+38,730
+1% +$4.04M
DYAX
9
DELISTED
DYAX CORPORATION
DYAX
$313M 2.59%
8,310,017
+748,537
+10% +$24.1M
DBVT
10
DBV Technologies
DBVT
$798M
$198M 1.64%
546,202
– –
ACOR
11
DELISTED
Acorda Therapeutics
ACOR
$153M 1.27%
29,834
+20,693
+226% +$90.4M
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.44B
$147M 1.22%
14,217,779
+107,600
+0.8% +$1.07M
BLCM
13
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$98.6M 0.82%
486,565
+67,506
+16% +$12.1M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$93.4M 0.77%
2,955,074
– –
CERS icon
15
Cerus
CERS
$577M
$85.7M 0.71%
13,553,275
– –
NGNE icon
16
Neurogene
NGNE
$643M
$84.2M 0.7%
337,367
– –
HRTX icon
17
Heron Therapeutics
HRTX
$92.5M
$77.6M 0.64%
2,907,784
– –
IMGN
18
DELISTED
Immunogen Inc
IMGN
$60.4M 0.5%
4,452,445
+904,405
+25% +$11.1M
ONCE
19
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$57.2M 0.47%
1,262,382
– –
NVTA
20
DELISTED
Invitae Corporation
NVTA
$53.8M 0.45%
6,554,967
– –
NBIX icon
21
Neurocrine Biosciences
NBIX
$18.3B
$48.1M 0.4%
850,739
+100,000
+13% +$5.08M
ARAV
22
DELISTED
Aravive, Inc. Common Stock
ARAV
$40.2M 0.33%
540,297
– –
SGMO
23
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$37M 0.31%
4,055,876
+300,000
+8% +$2.31M
HALO icon
24
Halozyme
HALO
$9.87B
$33.5M 0.28%
1,931,057
– –
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$32.8M 0.27%
609,166
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Baker Bros. Advisors held 141 positions worth $12.1B, up 12% from $10.8B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors withdrew a net $1.53B in Q4 2015, closing 8 positions and reducing 5 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $18.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 74% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Alkermes worth $19.9M.

  • Baker Bros. Advisors's largest Q4 2015 buy was Alkermes: 250,251 shares worth $19.9M.
  • Baker Bros. Advisors added most to Acorda Therapeutics in Q4 2015, an estimated $90.4M increase.
  • Baker Bros. Advisors's biggest Q4 2015 reduction was XENOPORT, INC., cutting an estimated $17M.
  • Baker Bros. Advisors fully exited Clovis Oncology, Inc. in Q4 2015, selling an estimated $18.6M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $12.1B portfolio in Q4 2015.
  • Baker Bros. Advisors opened 6 new positions and closed 8 in Q4 2015.
  • Baker Bros. Advisors's portfolio value rose 12% quarter-over-quarter to $12.1B.

Based on Baker Bros. Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.